ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Sinonasal microbiome remains stable during dupilumab therapy in chronic rhinosinusitis: a pilot study.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis prospective pilot study aimed to evaluate whether dupilumab therapy induces measurable changes in the sinonasal microbiome of patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
methodsEight CRSwNP patients fulfilling criteria for biologic therapy were treated with dupilumab 300 mg biweekly for six months. Nasal swabs from the middle meatus were collected immediately before therapy initiation and after six months. Alpha diversity and beta diversity metrics were assessed, and differential abundance analysis was performed.
resultsDupilumab therapy did not result in significant changes in alpha diversity, beta diversity, or taxonomic composition. Minor, non-significant reductions in richness and Shannon diversity were observed. Principal coordinate analysis showed extensive overlap between pre- and post-treatment samples, supported by a non-significant PERMANOVA. No statistically significant differentially abundant taxa were detected. In contrast to the microbiome results, clinical outcomes improved markedly over the same period, with all patients showing a reduction in SNOT-22 of at least 12 points and a decrease in Nasal Polyp Score of at least 1 point.
conclusionIn this pilot CRSwNP cohort, no significant changes in sinonasal microbial diversity or composition were detected over six months of dupilumab therapy, despite marked clinical improvement. Larger, controlled studies are required to detect subtle or delayed microbial changes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.